Radiopharm Theranostics Ltd. has been granted Bellberry Human Research Ethics Committee (HREC) approval in Australia to initiate a first-in-human phase I trial of its KLK3-targeting radiotherapeutic, RAD-402, for the treatment of metastatic or locally advanced prostate cancer.
Laekna Inc. outlicensed select rights to LAE-002 (afuresertib), an oral pan-AKT kinase inhibitor licensed from Novartis AG in 2018, to Qilu Pharmaceutical Co. Ltd. under a potential ¥2.045 billion (US$287.23 million) deal.
About a month after rolling out positive phase I/II data with its candidate for metastatic, castrate-resistant prostate cancer (mCRPC), Halda Therapeutics Inc. disclosed the plan by Johnson & Johnson (J&J), which is paying to take over the company for $3.05 billion in cash.
Laekna Inc. outlicensed select rights to LAE-002 (afuresertib), an oral pan-AKT kinase inhibitor licensed from Novartis AG in 2018, to Qilu Pharmaceutical Co. Ltd. under a potential ¥2.045 billion (US$287.23 million) deal.
Shenzhen Zhongge Biotechnology Co. Ltd. has divulged cholesterol side-chain cleavage enzyme, mitochondrial (CYP11A1) inhibitors reported to be useful for the treatment of castration-resistant prostate cancer.
Aussie radiopharma company Advancell Co. Ltd. unveiled promising early clinical data that could redefine how advanced prostate cancer is treated by targeted alpha therapies in the radiopharmaceutical space.
Kolm Therapeutics Inc. has disclosed heterobifunctional compounds comprising a disease-dependent protein binding moiety (particularly, CREB-binding protein [CREBBP; CBP] or histone acetyltransferase p300 [EP300]) covalently linked to a disease protein (particularly, androgen receptor) through a linker.
Aussie radiopharma company Advancell Co. Ltd. unveiled promising early clinical data that could redefine how advanced prostate cancer is treated by targeted alpha therapies in the radiopharmaceutical space.
Aussie radiopharma company Advancell Co. Ltd. unveiled promising early clinical data that could redefine how advanced prostate cancer is treated by targeted alpha therapies in the radiopharmaceutical space.
Changchung Genescience Pharmaceutical Co. Ltd., reported effects of the bispecific antibody-drug conjugate (ADC) of Gensci-143, is in metastatic castration-resistant prostate cancer (mCRPC) and other solid tumors.
